NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued on Wednesday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

NURO stock opened at $4.15 on Wednesday. The company’s 50-day moving average is $4.04 and its 200-day moving average is $3.84. The stock has a market capitalization of $8.47 million, a PE ratio of -0.90 and a beta of 2.29. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $4.73.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The firm had revenue of $0.59 million during the quarter. During the same quarter in the prior year, the firm posted ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.